ASTRO Names Richard Hoppe President-Elect

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

MIAMI BEACH--Richard Hoppe, MD, has been named president-elect of the American Society for Therapeutic Radiology and Oncology (ASTRO). Dr. Hoppe is chairman of the Department of Radiation Oncology at Stanford University School of Medicine. He will take office at the Society's annual meeting to be held in Los Angeles next October.

MIAMI BEACH--Richard Hoppe, MD, has been named president-electof the American Society for Therapeutic Radiology and Oncology(ASTRO). Dr. Hoppe is chairman of the Department of RadiationOncology at Stanford University School of Medicine. He will takeoffice at the Society's annual meeting to be held in Los Angelesnext October.

The current president, who took office at this year's ASTRO meeting,is Steven A. Leibel, MD, vice-chairman, clinical director, andEnid A. Haupt Chair, Department of Radiation Oncology, MemorialSloan-Kettering Cancer Center.

Other new officers announced at the meeting are: chairman of theboard, Jay R. Harris, MD, Joint Center for Radiation Therapy,Harvard Medical School; secretary, Karen K. Fu, MD, Universityof California, San Francisco, Mt. Zion Cancer Center; and treasurer,John D. Earle, MD, Mayo Medical School.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content